Fresenius Medical Care AG & Co. KGaA (FMS)
35.03 +0.02 (0.06%)
After hours: 4:00PM EST
Chart Events
Performance Outlook
| Previous Close | 35.36 |
| Open | 35.10 |
| Bid | 35.02 x 800 |
| Ask | 35.01 x 800 |
| Day's Range | 34.86 - 35.45 |
| 52 Week Range | 29.17 - 46.55 |
| Volume | 325,188 |
| Avg. Volume | 407,585 |
| Market Cap | 20.519B |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | 9.49 |
| EPS (TTM) | 3.69 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.72 (2.03%) |
| Ex-Dividend Date | Aug 28, 2020 |
| 1y Target Est | 37.57 |
Fair Value
Related Research
- Analyst Report: Fresenius Medical Care AG & Co. KGaA
- Analyst Report: Fresenius Medical Care AG & Co. KGaA
- Motley Fool
Fresenius Medical Care AG & Co. KGaA (FMS) Q4 2020 Earnings Call Transcript
FMS earnings call for the period ending December 31, 2020.
- Benzinga
Recap: Fresenius Medical Care Q4 Earnings
Shares of Fresenius Medical Care (NYSE:FMS) rose 0.0% after the company reported Q4 results. Quarterly Results Earnings per share fell 50.00% year over year to $0.76, which missed the estimate of $0.77. Revenue of $5,246,000,000 higher by 2.26% from the same period last year, which missed the estimate of $6,000,000,000. Guidance Earnings guidance hasn't been issued by the company for now. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 23, 2021 View more earnings on FMS Time: 09:30 AM ET Webcast URL: https://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=9256167&linkSecurityString=d6077a4d9 Technicals 52-week high: $46.55 Company's 52-week low was at $29.17 Price action over last quarter: down 6.85% Company Overview Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients in roughly 4,000 clinics across the globe as of December 2019. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Moody's
Fresenius Medical Care Holdings, Inc. -- Moody's announces completion of a periodic review of ratings of Fresenius Medical Care Holdings, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Fresenius Medical Care Holdings, Inc. Frankfurt am Main, January 19, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius Medical Care Holdings, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 14 January 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
